“Fast First and Then Slowly” Steroid-Tapering Regimen in Managing Corticoid-Sensitive Patients With Severe Immunotherapy Complications After Anti-PD-(L)1 Therapy for Cancer
Background: We aimed to assess the efficacy of the “fast first and then slowly” steroid-tapering regimen used in managing corticoid-sensitive patients with severe irAE after anti-PD-(L)1 therapy. Corticosteroids are the primary therapy for severe immune-related adverse events (irAEs). Less is known...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-11-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.1177/11795549231210475 |
| _version_ | 1797454351631908864 |
|---|---|
| author | Qi Gui Liping Xie Shaoqi Cheng Chengcheng Xu |
| author_facet | Qi Gui Liping Xie Shaoqi Cheng Chengcheng Xu |
| author_sort | Qi Gui |
| collection | DOAJ |
| description | Background: We aimed to assess the efficacy of the “fast first and then slowly” steroid-tapering regimen used in managing corticoid-sensitive patients with severe irAE after anti-PD-(L)1 therapy. Corticosteroids are the primary therapy for severe immune-related adverse events (irAEs). Less is known about the standard steroid-tapering regimen for corticoid-sensitive patients. Methods: This study was a single-center, retrospective medical record review of patients with severe irAE after anti-PD-(L)1 treatment for cancer from October 13, 2021 to October 20, 2022. The efficacy was assessed by Common Terminology Criteria for Adverse Events (CTCAE) grading system. Results: Among the 187 patients with severe irAEs associated with immune checkpoint inhibitors (ICIs), 136 (72.7%) cases were corticoid-sensitive, and 96 (51.3%) cases were scheduled “fast first and then slowly” steroid-tapering regimen. And of these, 87 (90.6%) cases got irAEs solution. Conclusions: The “fast first and then slowly” steroid-tapering regimen stayed shorter in the hospital. More studies are needed to confirm this efficacy and find more details about the steroid-tapering regimen. |
| first_indexed | 2024-03-09T15:37:04Z |
| format | Article |
| id | doaj.art-6c9f1c5a57964d8c99ee5f06915b80d0 |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-03-09T15:37:04Z |
| publishDate | 2023-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-6c9f1c5a57964d8c99ee5f06915b80d02023-11-26T04:33:19ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492023-11-011710.1177/11795549231210475“Fast First and Then Slowly” Steroid-Tapering Regimen in Managing Corticoid-Sensitive Patients With Severe Immunotherapy Complications After Anti-PD-(L)1 Therapy for CancerQi Gui0Liping Xie1Shaoqi Cheng2Chengcheng Xu3Department of Oncology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, People’s Republic of ChinaDepartment of Oncology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, People’s Republic of ChinaDepartments of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaDepartments of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaBackground: We aimed to assess the efficacy of the “fast first and then slowly” steroid-tapering regimen used in managing corticoid-sensitive patients with severe irAE after anti-PD-(L)1 therapy. Corticosteroids are the primary therapy for severe immune-related adverse events (irAEs). Less is known about the standard steroid-tapering regimen for corticoid-sensitive patients. Methods: This study was a single-center, retrospective medical record review of patients with severe irAE after anti-PD-(L)1 treatment for cancer from October 13, 2021 to October 20, 2022. The efficacy was assessed by Common Terminology Criteria for Adverse Events (CTCAE) grading system. Results: Among the 187 patients with severe irAEs associated with immune checkpoint inhibitors (ICIs), 136 (72.7%) cases were corticoid-sensitive, and 96 (51.3%) cases were scheduled “fast first and then slowly” steroid-tapering regimen. And of these, 87 (90.6%) cases got irAEs solution. Conclusions: The “fast first and then slowly” steroid-tapering regimen stayed shorter in the hospital. More studies are needed to confirm this efficacy and find more details about the steroid-tapering regimen.https://doi.org/10.1177/11795549231210475 |
| spellingShingle | Qi Gui Liping Xie Shaoqi Cheng Chengcheng Xu “Fast First and Then Slowly” Steroid-Tapering Regimen in Managing Corticoid-Sensitive Patients With Severe Immunotherapy Complications After Anti-PD-(L)1 Therapy for Cancer Clinical Medicine Insights: Oncology |
| title | “Fast First and Then Slowly” Steroid-Tapering Regimen in Managing Corticoid-Sensitive Patients With Severe Immunotherapy Complications After Anti-PD-(L)1 Therapy for Cancer |
| title_full | “Fast First and Then Slowly” Steroid-Tapering Regimen in Managing Corticoid-Sensitive Patients With Severe Immunotherapy Complications After Anti-PD-(L)1 Therapy for Cancer |
| title_fullStr | “Fast First and Then Slowly” Steroid-Tapering Regimen in Managing Corticoid-Sensitive Patients With Severe Immunotherapy Complications After Anti-PD-(L)1 Therapy for Cancer |
| title_full_unstemmed | “Fast First and Then Slowly” Steroid-Tapering Regimen in Managing Corticoid-Sensitive Patients With Severe Immunotherapy Complications After Anti-PD-(L)1 Therapy for Cancer |
| title_short | “Fast First and Then Slowly” Steroid-Tapering Regimen in Managing Corticoid-Sensitive Patients With Severe Immunotherapy Complications After Anti-PD-(L)1 Therapy for Cancer |
| title_sort | fast first and then slowly steroid tapering regimen in managing corticoid sensitive patients with severe immunotherapy complications after anti pd l 1 therapy for cancer |
| url | https://doi.org/10.1177/11795549231210475 |
| work_keys_str_mv | AT qigui fastfirstandthenslowlysteroidtaperingregimeninmanagingcorticoidsensitivepatientswithsevereimmunotherapycomplicationsafterantipdl1therapyforcancer AT lipingxie fastfirstandthenslowlysteroidtaperingregimeninmanagingcorticoidsensitivepatientswithsevereimmunotherapycomplicationsafterantipdl1therapyforcancer AT shaoqicheng fastfirstandthenslowlysteroidtaperingregimeninmanagingcorticoidsensitivepatientswithsevereimmunotherapycomplicationsafterantipdl1therapyforcancer AT chengchengxu fastfirstandthenslowlysteroidtaperingregimeninmanagingcorticoidsensitivepatientswithsevereimmunotherapycomplicationsafterantipdl1therapyforcancer |